Shares of Remedium Lifecare Ltd rose by 5% today, reaching Rs 6.95, up from yesterday’s closing price of Rs 6.65. Trading activity increased significantly, with over 1.7 million shares exchanged—more than 1.67 times the average level.
In a strategic move to support its rapid growth, Remedium Lifecare Ltd has established a wholly-owned subsidiary, REMLIFE GLOBAL PTE LTD, in Singapore. This new subsidiary, registered with the Accounting and Corporate Regulatory Authority under Corporate Entity Number 202439223M, aims to facilitate the acquisition of a major overseas project valued at approximately USD 200 million. To this end, Remedium has partnered with Wave Capital Limited, granting them exclusive rights as the Lead Manager for the project. Wave Capital will serve as the Lead Arranger, focusing on high-end businesses with a net worth of USD 100 million or more. This one-year agreement is expected to create significant opportunities for Remedium in strategic international markets.
Additionally, the company’s Board of Directors has approved a capital injection plan of USD 25 million, which will be raised through various instruments, including Foreign Currency Convertible Bonds (FCCB), private placements, rights issues, preferential issues, Follow-on Public Offers (FPO), Qualified Institutional Placements (QIP), Global Depository Receipts, and American Depository Receipts. This plan is subject to shareholder approval and regulatory confirmation.
Remedium is also partnering with Alpha Chem to support the growing electric vehicle (EV) industry. They have collaborated with Angel Partners Ltd. to acquire advanced lithium carbonate production technology and entered into a supply agreement with Alfa Chemicals and Solvents Ltd. for technical lithium carbonate worth between USD 20-25 million in 2025. This initiative positions Remedium to meet the rising demand for lithium-ion batteries in electric vehicles and portable electronics, allowing them to source lithium carbonate through contract manufacturing agreements in India.
In terms of financial performance, Remedium Lifecare Ltd reported net sales of Rs 77.70 crore and a net profit of Rs 1.64 crore for Q1 FY25. For FY24, the company achieved a total income of Rs 4,062.80 crore, reflecting a remarkable increase of 698% from FY23, along with a net profit of Rs 32.72 crore—up 504% from the previous year. Currently, the company has a market capitalization exceeding Rs 280 crore, and its stock price has experienced a 100% CAGR over the last three years.
Founded in 1988, Remedium Lifecare Ltd has become a significant player in the pharmaceutical value chain, importing and selling active pharmaceutical ingredients and intermediate chemicals to both innovative and generic drug manufacturers globally. They provide APIs for the production of various medications, including cholesterol reducers, antidepressants, and asthma and allergy treatments.
Disclaimer: The information provided in this report is for informational purposes only and should not be considered financial or investment advice. The performance of Remedium Lifecare Ltd shares, as well as the company’s strategic initiatives, are subject to market risks and uncertainties. Past performance is not indicative of future results. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. The author of this report is not responsible for any losses incurred as a result of reliance on the information provided herein.
Leave a Reply